ES2626801T3 - Compuestos de triazolopiridina como inhibidores de pde10a - Google Patents
Compuestos de triazolopiridina como inhibidores de pde10a Download PDFInfo
- Publication number
- ES2626801T3 ES2626801T3 ES12759445.5T ES12759445T ES2626801T3 ES 2626801 T3 ES2626801 T3 ES 2626801T3 ES 12759445 T ES12759445 T ES 12759445T ES 2626801 T3 ES2626801 T3 ES 2626801T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- halogen
- heteroaryl
- aryl
- hydroxyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Un compuesto de fórmula (I) **Fórmula** en la que R1 es arilo, heteroarilo o NR4R5, en el que dicho arilo y dicho heteroarilo pueden estar sustituidos con 1 a 3 sustituyentes seleccionados independientemente del grupo que consiste en hidroxilo, halógeno, alquilo C1-C7, alcoxi C1-C7 y haloalquilo C1-C7; R2 es hidrógeno, halógeno o alquilo C1-C7; R3 es arilo o heteroarilo, en el que dicho arilo y dicho heteroarilo pueden estar sustituidos con 1 a 3 sustituyentes seleccionados independientemente del grupo que consiste en alquilo C1-C7, hidroxilo, halógeno, -C(O)-NR6R7 y - C(O)-O-R8; R4 y R5 son independientemente alquilo C1-C7, cicloalquilo C3-C8, junto con el átomo de nitrógeno al que están unidos, forman un heterocicloalquilo que puede estar sustituido con 1 a 3 sustituyentes seleccionados independientemente del grupo que consiste en hidroxilo, halógeno, alquilo C1-C7, alcoxi C1-C7 y haloalquilo C1-C7; R6 y R7 son independientemente alquilo C1-C7, cicloalquilo C3-C8, junto con el átomo de nitrógeno al que están unidos, forman un heterocicloalquilo que puede estar sustituido con 1 a 3 sustituyentes seleccionados independientemente del grupo que consiste en hidroxilo, halógeno, alquilo C1-C7, alcoxi C1-C7 y haloalquilo C1-C7; R8 es hidrógeno, alquilo C1-C7, cicloalquilo; o una sal farmacéuticamente aceptable de los mismos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11181752 | 2011-09-19 | ||
EP11181752 | 2011-09-19 | ||
PCT/EP2012/068203 WO2013041472A1 (en) | 2011-09-19 | 2012-09-17 | Triazolopyridine compounds as pde10a inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2626801T3 true ES2626801T3 (es) | 2017-07-26 |
Family
ID=46851999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES12759445.5T Active ES2626801T3 (es) | 2011-09-19 | 2012-09-17 | Compuestos de triazolopiridina como inhibidores de pde10a |
Country Status (18)
Country | Link |
---|---|
US (2) | US8946427B2 (es) |
EP (1) | EP2758396B1 (es) |
JP (1) | JP2014526533A (es) |
KR (1) | KR101584925B1 (es) |
CN (1) | CN103827114B (es) |
AU (1) | AU2012311713A1 (es) |
BR (1) | BR112014006248A2 (es) |
CA (1) | CA2846758C (es) |
CL (1) | CL2014000641A1 (es) |
CO (1) | CO6900144A2 (es) |
EA (1) | EA201490599A1 (es) |
ES (1) | ES2626801T3 (es) |
IL (1) | IL231403A0 (es) |
MX (1) | MX2014003025A (es) |
PE (1) | PE20141553A1 (es) |
SG (1) | SG11201400759RA (es) |
UA (1) | UA108711C2 (es) |
WO (1) | WO2013041472A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013043520A1 (en) | 2011-09-22 | 2013-03-28 | Merck Sharp & Dohme Corp. | Triazolopyridyl compounds as aldosterone synthase inhibitors |
WO2013043518A1 (en) | 2011-09-22 | 2013-03-28 | Merck Sharp & Dohme Corp. | Imidazopyridyl compounds as aldosterone synthase inhibitors |
MY169128A (en) * | 2013-04-30 | 2019-02-18 | Hoffmann La Roche | Pd-catalyzed coupling of pyrazole amides |
TWI652014B (zh) | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
JP6568855B2 (ja) | 2014-07-30 | 2019-08-28 | 持田製薬株式会社 | ピラゾール誘導体の製造方法 |
CN107074844A (zh) * | 2014-07-30 | 2017-08-18 | 持田制药株式会社 | 吡唑衍生物的制造方法 |
CN107635984B (zh) | 2015-03-11 | 2021-04-13 | Fmc公司 | 杂环取代的二环唑杀有害生物剂 |
CN107743486B (zh) | 2015-03-12 | 2021-04-09 | Fmc公司 | 杂环取代的二环唑杀有害生物剂 |
US10800794B2 (en) | 2015-10-08 | 2020-10-13 | Fmc Corporation | Heterocycle-substituted bicyclic azole pesticides |
KR102600330B1 (ko) * | 2017-08-22 | 2023-11-10 | 바이엘 악티엔게젤샤프트 | 해충 방제제로서의 헤테로시클렌 유도체 |
JP7253049B2 (ja) | 2019-05-27 | 2023-04-05 | 日本農薬株式会社 | 架橋部に窒素原子を有する縮合複素環化合物又はその塩類及び該化合物を含有する農園芸用殺虫剤並びにその使用方法 |
AR119140A1 (es) | 2019-06-13 | 2021-11-24 | Pi Industries Ltd | Compuestos heterocíclicos fusionados y su uso como agentes de control de plagas |
CN110396157B (zh) * | 2019-08-07 | 2021-07-30 | 广州市建筑科学研究院有限公司 | 缓释型聚羧酸纳米减水剂及其制备方法和应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6355653B1 (en) * | 1999-09-06 | 2002-03-12 | Hoffmann-La Roche Inc. | Amino-triazolopyridine derivatives |
JP2007508241A (ja) | 2003-07-31 | 2007-04-05 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | Pde10a阻害剤を用いる糖尿病および関連障害の処置方法 |
NL2000397C2 (nl) * | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
WO2010035745A1 (ja) * | 2008-09-25 | 2010-04-01 | 杏林製薬株式会社 | ヘテロ環ビアリール誘導体及びそれらを有効成分とするpde阻害剤 |
WO2010059836A1 (en) * | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Substituted aza-bridged bicyclics for cardiovascular and cns disease |
WO2010117926A1 (en) * | 2009-04-07 | 2010-10-14 | Schering Corporation | Substituted triazolopyridines and analogs thereof |
WO2011036127A1 (en) * | 2009-09-24 | 2011-03-31 | F. Hoffmann-La Roche Ag | Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10a inhibitors |
CN112019976A (zh) | 2009-11-24 | 2020-12-01 | 诺基亚技术有限公司 | 用于处理音频信号的设备和方法 |
TWI485151B (zh) * | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之雜芳香族苯基咪唑衍生物 |
TW201200516A (en) * | 2009-12-17 | 2012-01-01 | Lundbeck & Co As H | Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors |
TWI487705B (zh) * | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之雜芳香族芳基三唑衍生物 |
-
2012
- 2012-09-17 EP EP12759445.5A patent/EP2758396B1/en not_active Not-in-force
- 2012-09-17 JP JP2014531187A patent/JP2014526533A/ja active Pending
- 2012-09-17 EA EA201490599A patent/EA201490599A1/ru unknown
- 2012-09-17 KR KR1020147009588A patent/KR101584925B1/ko not_active IP Right Cessation
- 2012-09-17 CN CN201280045398.XA patent/CN103827114B/zh not_active Expired - Fee Related
- 2012-09-17 UA UAA201404029A patent/UA108711C2/uk unknown
- 2012-09-17 MX MX2014003025A patent/MX2014003025A/es active IP Right Grant
- 2012-09-17 ES ES12759445.5T patent/ES2626801T3/es active Active
- 2012-09-17 AU AU2012311713A patent/AU2012311713A1/en not_active Abandoned
- 2012-09-17 CA CA2846758A patent/CA2846758C/en not_active Expired - Fee Related
- 2012-09-17 BR BR112014006248A patent/BR112014006248A2/pt not_active IP Right Cessation
- 2012-09-17 PE PE2014000366A patent/PE20141553A1/es not_active Application Discontinuation
- 2012-09-17 WO PCT/EP2012/068203 patent/WO2013041472A1/en active Application Filing
- 2012-09-17 SG SG11201400759RA patent/SG11201400759RA/en unknown
-
2014
- 2014-03-05 CO CO14047250A patent/CO6900144A2/es unknown
- 2014-03-06 IL IL231403A patent/IL231403A0/en unknown
- 2014-03-17 CL CL2014000641A patent/CL2014000641A1/es unknown
- 2014-03-18 US US14/218,275 patent/US8946427B2/en not_active Expired - Fee Related
- 2014-12-16 US US14/572,312 patent/US9227970B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
UA108711C2 (uk) | 2015-05-25 |
US8946427B2 (en) | 2015-02-03 |
AU2012311713A1 (en) | 2014-03-13 |
EP2758396A1 (en) | 2014-07-30 |
IL231403A0 (en) | 2014-04-30 |
CN103827114A (zh) | 2014-05-28 |
US9227970B2 (en) | 2016-01-05 |
KR20140075716A (ko) | 2014-06-19 |
WO2013041472A1 (en) | 2013-03-28 |
MX2014003025A (es) | 2014-05-28 |
KR101584925B1 (ko) | 2016-01-12 |
US20150099735A1 (en) | 2015-04-09 |
EA201490599A1 (ru) | 2014-07-30 |
CN103827114B (zh) | 2016-08-24 |
CA2846758C (en) | 2017-09-12 |
US20140303141A1 (en) | 2014-10-09 |
CO6900144A2 (es) | 2014-03-20 |
PE20141553A1 (es) | 2014-10-30 |
JP2014526533A (ja) | 2014-10-06 |
CA2846758A1 (en) | 2013-03-28 |
CL2014000641A1 (es) | 2014-11-14 |
BR112014006248A2 (pt) | 2017-04-11 |
EP2758396B1 (en) | 2017-03-29 |
SG11201400759RA (en) | 2014-07-30 |
NZ621597A (en) | 2015-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2626801T3 (es) | Compuestos de triazolopiridina como inhibidores de pde10a | |
AR079226A1 (es) | Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer | |
AR107616A1 (es) | Compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos | |
ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
AR098912A1 (es) | Inhibidores de syk | |
PE20160501A1 (es) | Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih | |
AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
AR080314A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa | |
ES2677919T3 (es) | Aminoalquil-quinazolonas sustituidas con pirimidina como inhibidores de la fosfatidilinositol 3-quinasa | |
AR092568A1 (es) | Derivados triciclicos de quinolinas y de quinoxalinas | |
AR092270A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
UY35641A (es) | PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO) | |
ECSP12012293A (es) | Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos | |
ECSP12012292A (es) | Ciertas amino-piridazinas, composicioines de las mismas y métodos de uso de los mismos | |
ES2722409T3 (es) | Moduladores de ROR gamma (RORy) | |
AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
ES2684517T3 (es) | Compuestos de heterociclilo como inhibidores de MEK | |
ES2603931T3 (es) | Compuestos de triazolo | |
AR078609A1 (es) | 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central,tales como depresion y canceres de ovario y renales, entre otros. | |
AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
AR110789A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
AR083760A1 (es) | Agentes antibacterianos y composiciones farmaceuticas | |
AR093184A1 (es) | Compuesto de pirimidina sustituida como inhibidor de quinurenina-3-monooxigenasa y composicion farmaceutica que lo comprenden |